Actively Recruiting
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate
Led by Mansoura University · Updated on 2025-06-11
110
Participants Needed
1
Research Sites
117 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
From previous studies, the investigators found that sexual outcomes after prostate surgery may show insignificant improvement, remain unchanged or deteriorate in non-negligible number of patients especially those with high preoperative IIEF scores. Deterioration of erectile function could be attributed to persistence of storage symptoms specially nocturia. Several pathophysiologic mechanisms, described before, are involved in pathogenesis of LUTS and ED and one can imagine that after relief of obstruction, the erectile function should improve, however lack of improvement or even deterioration suggests that damage associated with these mechanisms is irreversible and patients may require some sort of penile rehabilitation after surgery. The investigators hypothesized that Tadalafil may enhance relief of storage symptoms and enhance recovery of erectile function after surgery for BPH. With this assumption, a RCT was designed to examine the utility and efficacy of Tadalafil, once daily dose, to relieve persistent/ de novo storage symptoms and early erectile function deterioration after endoscopic prostate surgery.
CONDITIONS
Official Title
Efficacy of Tadalafil (5mg) For Treatment of Early Storage Symptoms and Erectile Dysfunction After Endoscopic Enucleation of Prostate
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients aged 40 years or older
- Diagnosed with lower urinary tract symptoms secondary to bladder outlet obstruction caused by benign prostatic hyperplasia that did not improve with medical treatment
- International prostate symptom score (IPSS) greater than 15 with a bother score (quality of life) of 3 or higher
- Peak urinary flow rate (Qmax) less than 15 ml/sec
- American Society of Anesthesiologists (ASA) score of 3 or less
- Sexually active men not currently using phosphodiesterase type 5 inhibitors (PDE5I)
You will not qualify if you...
- Use of nitrates, potassium channel openers, or alpha-1 blockers like doxazosin and terazosin for hypertension
- History of unstable angina, recent heart attack, stroke, or heart failure
- Severe liver or kidney failure
- Sexual inactivity
- Uncontrolled diabetes or neurological conditions such as Parkinson's disease
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Urology and Nephrology Center
Al Mansurah, Dakahlia Governorate, Egypt, 35516
Actively Recruiting
Research Team
M
Mahmoud Laymon, MD,MRCS
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here